Pazopanib and liposomal doxorubicin in the treatment of patients with relapsed/refractory epithelial ovarian cancer: a phase Ib study of the Sarah Cannon Research Institute

Autor: Cynthia C. Chua, Chris Earwood, John D. Hainsworth, Irfan Firdaus

Publikováno v: Cancer investigation. 33(3)

Purpose: To investigate the combination of liposomal doxorubicin/pazopanib in advanced relapsed/refractory ovarian cancer. Patients and Methods: Twenty-two patients received liposomal doxorubicin/pazopanib. Initial doses (liposomal doxorubicin, 40 mg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e7fd1ada2a78976b161ca5e7a7d9531
https://pubmed.ncbi.nlm.nih.gov/25615852

Thalidomide and rituximab in Waldenstrom macroglobulinemia.

Autor: Treon SP; Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA. steven_treon@dfci.harvard.edu, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, Briccetti FM, Pasmantier M, Zimbler H, Cooper RB, Moore M, Hill J 2nd, Rauch A, Garbo L, Chu L, Chua C, Nantel SH, Lovett DR, Boedeker H, Sonneborn H, Howard J, Musto P, Ciccarelli BT, Hatjiharissi E, Anderson KC

Publikováno v: Blood [Blood] 2008 Dec 01; Vol. 112 (12), pp. 4452-7. Date of Electronic Publication: 2008 Aug 19.